Heavy menstrual bleeding: a plain-language guide
Heavy menstrual bleeding, also called menorrhagia, is menstrual bleeding heavy enough or long enough to affect a person’s daily life, and it is now judged by that impact rather than by measuring blood loss [1].
This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.
Key facts
- Heavy menstrual bleeding is bleeding heavy or long enough to interfere with daily life, and guidelines say treatment should aim to improve quality of life rather than focus on the amount of blood lost [1].
- Useful markers include changing a pad or tampon every one to two hours, needing two types of protection at once, bleeding through to clothes or bedding, passing clots larger than about 2.5 cm, waking at night to change, and periods lasting more than seven days [4,5].
- In the United States it affects more than 10 million women each year, about one in five [5].
- Causes are grouped into structural ones, such as polyps, adenomyosis and fibroids, and non-structural ones, such as clotting problems, ovulation problems and side effects of medicines [7,8].
- An underlying bleeding disorder is found in a meaningful minority, and von Willebrand disease is the most common one in women and girls [5,9].
- Low iron and anemia are the most common consequences, and being told you are low in iron is itself a reason to ask about heavy periods [5,9].
On this page
- What is heavy menstrual bleeding?
- How common is it?
- What causes it?
- What are the symptoms?
- How is it diagnosed?
- How is it treated?
- Living with heavy menstrual bleeding
- Thinking about a clinical trial?
- Current research
- Support and further information
- Questions people often ask
- Related trialport information
- Sources
- Review information
What is heavy menstrual bleeding?
Heavy menstrual bleeding is menstrual bleeding heavy enough, or long enough, to get in the way of ordinary life. The older name is menorrhagia. It is a symptom rather than a disease, and one form of what doctors call abnormal uterine bleeding, which also covers bleeding between periods [4,5,8].
How doctors define it has changed, and that shift is the most useful thing on this page. Older definitions set a number, 80 mL of blood or more in a period, which cannot be measured in ordinary practice and said little about how someone was coping [7]. National guidance in the United Kingdom now says plainly that heavy menstrual bleeding has a major impact on quality of life, and that treatment should aim to improve that rather than focus on blood loss [1].
The same guidance asks doctors to allow for how much periods vary between people and, if a woman feels hers fall outside the usual range, to discuss care options with her [1]. Your own sense that something is not right is a reasonable place to start.
How common is it?
In the United States it affects more than 10 million women each year, about one in five [5]. In the United Kingdom, about 1 in 20 women aged 30 to 49 see their family doctor each year about heavy periods or other menstrual problems [2].
Estimates vary widely: across countries, abnormal uterine bleeding is thought to affect 3 to 30 percent of women of reproductive age, and a European survey found heavy bleeding in 27 percent [7].
These figures mostly count people who report symptoms or seek care rather than people whose blood loss has been measured, and many never seek help, so the true number is probably higher [7]. Comparable regional figures are unavailable.
What causes it?
Doctors worldwide use one shared list of causes, known as PALM-COEIN and revised by the International Federation of Gynecology and Obstetrics in 2018 [8]. The first four are structural, meaning visible on a scan or under a microscope. More than one can be present, and often no cause is found [5,7].
Structural causes:
- Polyps, small soft growths on the lining of the uterus, or womb, usually harmless.
- Adenomyosis, lining tissue growing into the muscle wall of the uterus, often with heavy or painful periods.
- Leiomyomas, or fibroids: non-cancerous knots of muscle in the uterine wall, which can bleed heavily.
- Malignancy and hyperplasia, cancer of the lining or overgrowth preceding it. Uncommon before menopause, and why doctors sometimes take a sample.
Non-structural causes:
- Coagulopathy, a clotting problem, common in teenagers and young adults [7].
- Ovulatory dysfunction, where eggs are not released regularly, as in thyroid problems, polycystic ovary syndrome and the years around the first and last periods [7].
- Endometrial causes, where the lining fails to control bleeding although it looks normal.
- Iatrogenic causes, side effects of treatment: anticoagulants, aspirin and a copper coil can increase bleeding [5,7].
- Not otherwise classified, rarer causes such as abnormal blood vessels in the uterus.
Von Willebrand disease is the most common bleeding disorder in women and girls, affecting up to 1 percent of the United States population, and women notice it more because periods are where it shows [9]. If a routine gynecology visit has found no problem, ask to be tested for a bleeding disorder [5]. Our guide to von Willebrand disease covers it in full.
What are the symptoms?
The most useful thing to bring to an appointment is concrete detail. These are the markers health services use [4,5,9]:
- changing a pad or tampon every one to two hours
- needing two types of protection together, such as a pad and a tampon
- bleeding through to clothes or bedding, sometimes called flooding
- needing to change during the night
- periods lasting more than seven days
- passing clots larger than about 2.5 cm, the size of a quarter
- feeling tired or short of breath
- missing work, school, exercise or social plans
Low iron is the most common consequence and is often missed. Monthly blood loss drains iron stores, which can lead to anemia, a shortage of red blood cells that carry oxygen [5]. Being told you are low in iron is itself worth raising [9].
When to seek urgent help. Get same-day medical help if you are soaking more than one pad an hour for several hours, or if you feel faint or dizzy, have a very fast heartbeat, or are breathless at rest [7]. Otherwise, see a doctor if heavy periods are affecting your life, or if you bleed between periods [4].
How is it diagnosed?
Diagnosis usually starts with a family doctor and may involve a gynecologist. The first step is a conversation covering the nature of the bleeding, related symptoms such as pelvic pain, and the effect on your quality of life [1].
A full blood count is recommended for everyone, and can be done at the same time as starting treatment rather than before it [1]. A pregnancy test is standard, and doctors often check ferritin, which shows iron stores [7]. Testing for a clotting disorder should be considered for anyone whose periods have been heavy since they started and who has a personal or family history suggesting one [1], or who has been treated for anemia or bled heavily after tooth extraction, surgery or childbirth [7].
Not everyone needs a scan: treatment can start without investigating the cause when the history suggests a low chance of fibroids, adenomyosis or a lining problem. A vaginal ultrasound is preferred when period pain is significant or the uterus feels bulky and tender. Hysteroscopy, looking inside the uterus with a thin telescope, comes first when polyps, fibroids in the cavity or a lining problem are suspected, and a biopsy may be taken at the same time [1]. It can be stopped at any point if it hurts too much [10].
Diagnosis is often slow, since many people do not realize their periods are outside the usual range and the symptom is frequently overlooked. One research program aims to cut the average wait for effective treatment from about five years to five months [12].
How is it treated?
Heavy periods do not always need treating [4]. The choice depends on your preferences, whether a cause has been found, whether you want to keep your fertility, and your other symptoms [1].
First choice medicine. A levonorgestrel-releasing intrauterine system, a small hormone-releasing device placed in the uterus, is the recommended first treatment when no cause has been found, when fibroids are under 3 cm and not distorting the cavity, or when adenomyosis is suspected. Allow six cycles to judge the benefit [1].
Other medicines. If that device is declined or unsuitable, the options are tranexamic acid, anti-inflammatory painkillers such as naproxen, combined hormonal contraception, and cyclical progestogen tablets [1]. Tranexamic acid cuts blood loss by roughly a quarter to a half, suits people trying to conceive, and is used alongside iron treatment where iron is low [5,7].
Where fibroids are 3 cm or larger, the options widen to include uterine artery embolization, which blocks their blood supply, and myomectomy, removal of the fibroids [1]. A tablet containing relugolix, a gonadotrophin-releasing hormone blocker, is recommended in the United Kingdom for moderate to severe fibroid symptoms [11].
Surgery and fertility. If medicines have not worked, specialist options include endometrial ablation, which removes or destroys the lining, and hysterectomy. Embolization and myomectomy may allow you to keep your fertility; after ablation you are advised to avoid pregnancy; hysterectomy ends it. Anyone considering hysterectomy should have a full discussion first, covering sexual feelings, fertility, bladder function, complications and alternatives [1].
Where a bleeding disorder is the cause, treatment may include tranexamic acid or desmopressin [7]. There is no single cure, and availability differs by country.
Living with heavy menstrual bleeding
Tracking your periods before an appointment helps more than almost anything. Note the dates, the heavy days, how many pads or tampons you used, whether you passed clots, and what you canceled [5]. Numbers are harder to dismiss than adjectives.
Ask for your iron and blood count to be checked, and take iron treatment as advised if it is low [5,7]. Check other medicines, since aspirin and anticoagulants can make bleeding heavier [5].
When offered a choice, one professional body suggests three questions: what are my options, what are the pros and cons, and how do I get support to decide [10].
Thinking about a clinical trial?
Clinical trials are research studies that test whether a treatment works and is safe. Deciding whether to look into one is a personal choice, and it helps to take it in steps.
1. Understand what the study is asking
It is worth being clear on what a study involves:
- what the researchers are trying to learn
- what treatment is being studied, and what it is compared with
- how long it lasts, and how many menstrual cycles it covers
- what visits and tests are involved, how often, and how far you would travel
- the possible benefits, and the known and unknown risks
- what happens at the end, including whether treatment continues
2. Consider possible medical suitability
Every trial has rules about who can take part, called eligibility criteria. For a heavy menstrual bleeding study they might include an age range, regular cycles, bleeding above a set level recorded on a menstrual chart or scored questionnaire, a hemoglobin or ferritin level within a given range, whether a cause such as fibroids has been found, whether you have already tried a particular treatment, and not being pregnant.
trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.
Explore heavy menstrual bleeding clinical trials through trialport
3. Consider whether participation fits your life
Medical suitability is only part of the picture. A study can look right on paper and still be hard in practice. Worth thinking through:
- the time each visit takes, and who would come along
- work, school or caring responsibilities, and support from family and friends
- how you feel about internal examinations, scans or repeated blood tests
- whether you are willing to keep a daily bleeding record, sometimes by collecting used products for measurement
- whether you understand the study well enough to decide
trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.
4. Ask questions before deciding
Useful questions to put to a research team:
- Why is this study being carried out, and what is already known?
- What exactly would I need to do, and for how long?
- What are the known risks, and what is still unknown?
- Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly.
- Would I have to stop the treatment I use now, and would my iron level be checked?
- Could this treatment affect my fertility, now or later?
- Can I leave after joining, are costs covered, and will I be told the results?
Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.
Search for clinical trials at app.trialport.com.
Current research
- A coordinated push on the basics. An international program called The Missed Vital Sign is investing 50 million US dollars in measuring heavy menstrual bleeding better and developing treatments [12].
- A treatment that is neither hormonal nor surgical. One funded team is developing a vaginal gel to deliver mRNA into the lining of the uterus, restoring proteins that limit bleeding. This is at the laboratory and animal stage [12].
- A medicine aimed at clot stability. HMB-003 is an investigational injection under the skin designed to slow the breakdown of clots, with heavy menstrual bleeding as its first target. Animal results were reported in July 2026, and it is not approved [13].
- A wearable nerve stimulation device. A small pilot study of a device worn on the ear, published in Bioelectronic Medicine in 2026, reported reductions in blood loss and symptoms. It was open label, so it is an early step rather than proof [14].
- Open questions in the guidelines, including which first test works best [3].
Study status checked: 3 August 2026. Research moves, so this list will date. For current information, search at app.trialport.com.
Support and further information
In the United Kingdom, the NHS page on heavy periods is a practical starting point, and the NHS signposts the Wellbeing of Women periods information hub [4]. NICE’s information for the public sets out the care you should expect, which helps if you feel unheard [2]. The Royal College of Obstetricians and Gynaecologists publishes plain leaflets on the procedures [10]. In the United States, the Centers for Disease Control and Prevention pages cover symptoms, tests and a period-tracking chart [5,6], and the National Bleeding Disorders Foundation explains how to reach a specialist center [9]. Verified support elsewhere is thinner.
Questions people often ask
I have been told my periods are normal for me. How do I know they are not?
No single number settles it. Guidance judges heavy menstrual bleeding by its effect on your life, and asks doctors to discuss care options if you feel your periods fall outside the usual range [1]. Changing protection every one to two hours, using two products at once, flooding, or bleeding beyond seven days are recognized markers [4,5].
How do I explain it so I am taken seriously?
Bring numbers: days of bleeding, products used per day, clot size, nights disturbed, days missed [5]. Mention any past low iron result and family history of easy bleeding [9].
Does heavy bleeding mean cancer?
Rarely. Cancer of the lining is one cause among many and is uncommon before menopause [4,7]. Taking a small sample is normal checking rather than a sign of bad news [1].
Will I end up needing a hysterectomy, and can I still get pregnant?
Most people never need a hysterectomy, since medicines are tried first and uterus-sparing procedures sit in between. Tranexamic acid suits people trying to conceive, and embolization or fibroid removal may allow fertility to be kept, while pregnancy should be avoided after ablation [1,7].
Should I be tested for a bleeding disorder?
Ask, particularly if your periods have been heavy since they started, if a relative bleeds easily, or if a gynecology check has found nothing [1,5,9].
Related trialport information
- Search for heavy menstrual bleeding clinical trials
- Understanding von Willebrand disease: a plain-language guide
- How clinical trials work
- Questions to ask a clinical trial team
- Understanding informed consent
- medifit and readifit explained
- More guides to women’s health and to blood and bleeding conditions
Sources
- National Institute for Health and Care Excellence. Heavy menstrual bleeding (NICE guideline NG88): Recommendations. Published 14 March 2018, last updated 24 May 2021. https://www.nice.org.uk/guidance/ng88/chapter/Recommendations Accessed 3 August 2026.
- National Institute for Health and Care Excellence. Heavy menstrual bleeding: the care you should expect. Information for the public, NG88. https://www.nice.org.uk/guidance/ng88/informationforpublic Accessed 3 August 2026.
- National Institute for Health and Care Excellence. Heavy menstrual bleeding (NICE guideline NG88): Recommendations for research. https://www.nice.org.uk/guidance/ng88/chapter/Recommendations-for-research Accessed 3 August 2026.
- NHS. Heavy periods. Page last reviewed 19 September 2024. https://www.nhs.uk/conditions/heavy-periods/ Accessed 3 August 2026.
- Centers for Disease Control and Prevention. About Heavy Menstrual Bleeding. Last reviewed 16 May 2024. https://www.cdc.gov/female-blood-disorders/about/heavy-menstrual-bleeding.html Accessed 3 August 2026.
- Centers for Disease Control and Prevention. About Bleeding Disorders in Women. Last reviewed 16 May 2024. https://www.cdc.gov/female-blood-disorders/about/index.html Accessed 3 August 2026.
- Mikes BA, Vadakekut ES, Sparzak PB. Abnormal Uterine Bleeding. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Updated 21 February 2025. NCBI Bookshelf ID NBK532913. https://www.ncbi.nlm.nih.gov/books/NBK532913/ (PMID 30422508). Accessed 3 August 2026.
- Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. International Journal of Gynecology & Obstetrics. 2018;143(3):393-408. doi:10.1002/ijgo.12666. https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.12666 (PMID 30198563). Accessed 3 August 2026.
- National Bleeding Disorders Foundation. Women and Bleeding Disorders: Diagnosis and Care. https://www.bleeding.org/bleeding-disorders-a-z/overview/women-and-bleeding-disorders Accessed 3 August 2026.
- Royal College of Obstetricians and Gynaecologists. Outpatient hysteroscopy. Patient information, last reviewed 7 April 2025. https://www.rcog.org.uk/for-the-public/browse-our-patient-information/outpatient-hysteroscopy/ Accessed 3 August 2026.
- National Institute for Health and Care Excellence. Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832): Recommendations. https://www.nice.org.uk/guidance/ta832/chapter/1-Recommendations Accessed 3 August 2026.
- Weir K. New research seeks an mRNA therapy for heavy menstrual bleeding. Penn Medicine News, University of Pennsylvania, 11 September 2025. https://www.pennmedicine.org/news/new-research-seeks-an-mrna-therapy-for-heavy-menstrual-bleeding Accessed 3 August 2026.
- Hemab Therapeutics. Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress. Press release, 12 July 2026. https://ir.hemab.com/news-releases/news-release-details/hemab-therapeutics-presents-new-clinical-data-hmb-002-von Accessed 3 August 2026.
- Spark Biomedical. New Wearable Technology Shows Clinically Meaningful Reductions in Heavy Menstrual Bleeding. Press release, 16 April 2026. https://www.globenewswire.com/news-release/2026/04/16/3275440/0/en/New-Wearable-Technology-Shows-Clinically-Meaningful-Reductions-in-Heavy-Menstrual-Bleeding.html Accessed 3 August 2026.
Review information
Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026